Double-Drug attack on rheumatoid arthritis shows promise in new trial

NCT ID NCT04870203

Ongoing Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase III trial tests whether combining baricitinib with an anti-TNF drug (adalimumab or etanercept) works better than baricitinib alone for people with rheumatoid arthritis who haven't responded to prior treatments. The study involves 160 adults aged 18-65 with active disease. Researchers will measure how many patients achieve a 50% improvement in symptoms (ACR50) and track side effects over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baricitinib and anti-TNF drugs (adalimumab or etanercept)
What this could lead to: If successful, this combination could offer a more effective treatment option for people with rheumatoid arthritis who haven't responded well to other therapies.
What could go wrong: This is a relatively small Phase III trial (160 participants). Combining these drugs may increase the risk of serious side effects, and the benefit may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

AP-HM - service de rhumatologie

Marseille, France
AP-HP - Hopital Avicenne - service de rhumatologie

Bobigny, France
AP-HP - Hôpital Bichat - service de rhumatologie

Paris, France
AP-HP - Hôpital Cochin - service de rhumatologie

Paris, France
AP-HP - Hôpital Kremlin-Bicêtre - service de rhumatologie

Le Kremlin-Bicêtre, France
AP-HP - Hôpital La Pitié-Salpetrière - service de rhumatologie

Paris, France
AP-HP - Hôpital Saint-Antoine - service de rhumatologie

Paris, France
CH Emile Roux - service rhumatologie

Le Puy-en-Velay, France
CH de Belfort - service de rhumatologie

Belfort, France
CH de Dax - service de rhumatologie

Dax, France
CH de Niort - service de rhumatologie

Niort, France
CH de Pau - service de rhumatologie

Pau, France
CH de Reims - service de rhumatologie

Reims, France
CH de Saint-Malo - service de rhumatologie

St-Malo, France
CH de la Côte Basque - service de rhumatologie

Bayonne, France
CH du Mans - service de rhumatologie

Le Mans, France
CHD VENDEE - service de rhumatologie

La Roche-sur-Yon, France
CHRU de Nancy - service de rhumatologie

Vandœuvre-lès-Nancy, France
CHRU de Strasbourg - service de rhumatologie

Strasbourg, France
CHRU du Tours - service de rhumtologie

Tours, France
CHU de Bordeaux - service de rhumatologie

Bordeaux, France
CHU de Brest - Service de rhumatologie

Brest, France
CHU de Clermont-Ferrand - service de rhumatologie

Clermont-Ferrand, France
CHU de Montpellier - service de rhumatologie

Montpellier, France
CHU de Nice - service de rhumatologie

Nice, France
CHU de Nîmes - service de rhumatologie

Nîmes, France
CHU de Saint-Etienne- service de rhumatologie

Saint-Etienne, France
CHU de Toulouse - service de rhumatologie

Toulouse, France
Clinique de l'Infirmerie - service de rhumatologie

Caluire-et-Cuire, France
Groupement des Hôpitaux de l'Institut Catholique de Lille - service de rhumatologie

Lomme, France
Hopital NOVO - service de rhumatologie

Pontoise, France
Hospices Civils de Lyon - service de rhumatologie

Pierre-Bénite, France
Hôpital Saint-Joseph - service de rhumatologie

Marseille, France
Nouvel Hôpital Orléans La Source - service de rhumatologie

Orléans, France
Polyclinique de Limoges - service de rhumatologie

Limoges, France
service de Rhumatologie - CH Princesse Grace

Monaco, Monaco

More trials for these conditions

Other studies related to the condition(s) this trial covers.